Zosano Pharma Corporation reported impairment charges for the first quarter ended March 31, 2022. For the quarter, the company reported impairment loss of $25.9 million for the three months ended March 31, 2022, consists of the write-down of $24.8 million of property and equipment and $1.1 million of right-of-use assets.
Zosano Pharma Corporation
Equities
ZSAN
US98979H3012
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |